Close Menu

NEW YORK (GenomeWeb) – Biocept today priced its public offering of more than 4.9 million shares of common stock at $.68 per share.

Net proceeds from the offering, expected to close on or about Dec. 7, is anticipated to be $3 million, which will go toward working capital and other general corporate purposes, Biocept said. The firm noted that no warrants to purchase shares of its common stock will be issued to investors in connection with the offering.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.

In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.

MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.

In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.